SecBot SecBot
SECBOTREPLAY Home › Report › HOWL

HOWL · Ambros-Werewolf merger update

Werewolf Therapeutics, Inc. · 425 filed Nov 9, 2026 at 21:49 ET

At the news

NEUTRALIMPACT 5/10

425 filed Nov 9, 2026 at 21:49 ET

Ambros Therapeutics presented an Analyst Day deck detailing its pending reverse merger with Werewolf Therapeutics (HOWL), including a concurrent $150M PIPE co-led by RA Capital Management and Janus Henderson Investors. The combined company is valued at ~$697.5M pro forma, with Ambros implied at $500M and Werewolf at $47.5M. The deal is expected to close in Q4 2026, and the combined entity will trade as 'AMBX' with proceeds funding the CRPS-RISE pivotal trial of neridronate through NDA submission.

  • Reverse triangular merger of Werewolf subsidiary into Ambros; Ambros survives as wholly owned subsidiary.
  • Pro forma combined company value at closing: ~$697.5M.
  • Implied valuation for Ambros: $500M (before concurrent PIPE).
  • Implied valuation for Werewolf: $47.5M ($30M net cash + $17.5M Nasdaq listing value).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access